To characterize the involvement of Gal-3 in the response of melanoma cells to the treatment with PLX-4032, a BRAF enzyme inhibitor used in the clinics to treat melanoma patients who have the BRAFV600E mutation [29, 30], we first evaluated the distribution of cells in distinct cell cycle phases and cell death in Gal-3 silenced cells treated with PLX4032. This evidence concerns the gene BRAF and melanoma.